AMP’s Participates in the Ceremony to Introduce the MenAfriVacTM Vaccine in Burkina Faso

MenAfriVac immunization

March 8, 2017

On March 6, 2017, AMP participated in the official ceremony for the introduction of MenAfriVacTM vaccine against meningococcal meningitis serogroup A in Burkina Faso’s Expanded Program on Immunization (EPI). The Health Minister, Professor Nicolas Meda, and the technical and financial partners participated in the ceremony at the Health and Social Promotion Center (CSPS), in Dassasgho, Ouagadougou.

Located in the African meningitis belt, Burkina Faso has had its fair share of epidemics. In response, immunization campaigns are constantly carried out during outbreaks. This new campaign aims to provide coverage for the first three years with 70% in the first year, 2017, 90% in 2018, and 100% in 2019.

After an introductory speech by the CSPS director, a visit to an immunization unit gave each of the partners a chance to administer a dose of the new vaccine to a group of 15-month-old children. The partners included the Health Minister; WHO representative, Dr. Alimata Diarra-Nama; UNICEF representative, Dr. Anne Vincent; CDC Director in Burkina Faso, Dr. Rebecca Greco Kone; Governor Representative of the region, Centre, Dr. Joachim Somda; and AMP’s Director in Burkina Faso, Dr. Edouard Betsem.  

During the ceremony, the team were also able to see the effectiveness of the new stamps in the immunization records, an initiative supported by AMP and CDC, which documents MenAfrivacTM and RR2 (rubella, measles) vaccines that are administered to 15-month-old children.